Nucleic acids encoding a polypeptide containing a modified FC region of human IgG1 and at least one heterologous antigen.

Nucleic acids encoding polypeptides with a modified Fc region of human IgG1, incorporating mouse IgG3 residues, address the challenge of stimulating high-avidity T cell and antibody responses, enhancing immune responses against cancer and pathogens.

JP7885202B2Inactive Publication Date: 2026-07-06SCANCELL
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SCANCELL
Filing Date
2021-08-25
Publication Date
2026-07-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing vaccines fail to stimulate robust high-avidity CD8 T cell and Th1 CD4 T cell responses and potent antibody responses, particularly in the context of cancer and infectious diseases, due to insufficient antigen presentation and immune evasion by tumors or pathogens.

Method used

The development of nucleic acids encoding polypeptides with a modified Fc region of human IgG1 that enhances avidity to Fc gamma receptors (FcγR) by incorporating residues from mouse IgG3, promoting non-covalent oligomerization and efficient antigen presentation, thereby stimulating high-avidity T cell responses and antibody production.

Benefits of technology

The modified Fc region significantly enhances immunogenicity, leading to improved cellular and humoral responses against heterologous antigens, including potent CD8 T cell and antibody responses, effectively targeting cancer cells and pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007885202000011
    Figure 0007885202000011
  • Figure 0007885202000012
    Figure 0007885202000012
  • Figure 0007885202000013
    Figure 0007885202000013
Patent Text Reader

Abstract

The present invention relates to nucleic acids and peptides encoded by the nucleic acids. In particular, the peptides comprise a modified IgG1 Fc region and one or more heterologous epitopes, which may be B cell or T cell epitopes. The nucleic acids of the invention may encode polypeptides comprising (i) a modified Fc region of human IgG1 and (i) at least one heterologous antigen, wherein (a) the modified Fc region comprises at least a portion of an Fc capable of binding to CD64 and / or TRIM21, (b) at least one residue of the Fc region has been modified to the corresponding residue of a murine IgG3 antibody, and (c) the modified Fc region has enhanced avidity for Fc gamma receptors (FcγRs) compared to the corresponding wild-type Fc region.
Need to check novelty before this filing date? Find Prior Art